Neuroprotective agents target molecular mechanisms of disease in ALS

Drug Discovery Today

Volumn 20, Issue 1, 2015, Pages 65-75

  Zhu, Yongjin ^a   Fotinos, Anastasios ^a   Mao, Lilly L J ^b   Atassi, Nazem ^c   Zhou, Edward W ^a   Ahmad, Sarfraz ^b   Guan, Yingjun ^d   Berry, James D ^c   Cudkowicz, Merit E ^c   Wang, Xin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Aimcan Pharma Research and Technologies   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARIMOCLOMOL; CELASTROL; CYCLOSPORIN A; DP 109; DP 460; FETCPP; GLUTAMIC ACID; GUANABENZ; LENALIDOMIDE; M 30; NAPB; NEUROPROTECTIVE AGENT; NORDIHYDROGUAIARETIC ACID; OLESOXIME; PIOGLITAZONE; PROTEASOME; RILUZOLE; THALIDOMIDE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EXCITOTOXICITY; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; MUSCLE ATROPHY; MUSCLE INJURY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RESPIRATORY FAILURE; REVIEW; STRUCTURE ACTIVITY RELATION; SURVIVAL; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; MUSCULAR ATROPHY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MUSCULAR ATROPHY; NEUROPROTECTIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; WEIGHT LOSS;

EID: 84922447883     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.016     Document Type: Review

References (99)

1. Rosen, D.R. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62
2. Haeusler, A.R. et al. (2014) C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507, 195-200
3. Miller, R.G. et al. (1996) Clinical trials of riluzole in patients with ALS. Neurology 47 (Suppl. 2), 86-92
4. Kasarskis, E.J. and Neville, H.E. (1996) Management of ALS nutritional care. Neurology 47 (Suppl. 2), 118-120
5. Körner, S. et al. (2013) Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol. 13, 84
6. Ngo, S. et al. (2014) Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 340, 5-12
7. Nau, K.L. et al. (1995) Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass. J. Neurol. Sci. 129, 47-49
8. Lee, C.D. et al. (2010) Muscle ultrasound quantifies the rate of reduction of muscle thickness in amyotrophic lateral sclerosis. Muscle Nerve 42, 814-819
9. Mazzini, L. et al. (1995) Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J. Neurol. 242, 695-698
10. Goyal, N.A. and Mozaffar, T. (2014) Respiratory and nutritional support in amyotrophic lateral sclerosis. Curr. Treat. Options Neurol. 16, 1-12
11. Kidney, D. et al. (2004) Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales. Amyotroph. Lateral Scler. 5, 150-153
12. Dupuis, L. et al. (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U. S. A. 101, 11159-11164
13. Bouteloup, C. et al. (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J. Neurol. 256, 1236-1242
14. Desport, J.C. et al. (2006) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener. Dis. 2, 202-207
15. Bendotti, C. et al. (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J. Neurol. Sci. 191, 25-33
16. Crugnola, V. et al. (2010) Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol. 67, 849-854
17. Piquet, M. (2006) Nutritional approach for patients with amyotrophic lateral sclerosis. Revue Neurol. 162 4S177-4S187 (in French).
18. Desport, J.C. et al. (2000) Nutritional assessment and survival in ALS patients. Amyotroph. Lateral Scler. 1, 91-96
19. Desport, J.C. et al. (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53, 1059-1063
20. Heffernan, C. et al. (2004) Nutritional management in MND/ALS patients: an evidence based review. Amyotroph. Lateral Scler. 5, 72-83
21. Paganoni, S. et al. (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44, 20-24
22. Jawaid, A. et al. (2010) A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph. Lateral Scler. 11, 542-548
23. Scarmeas, N. et al. (2002) Premorbid weight, body mass, and varsity athletics in ALS. Neurology 59, 773-775
24. Gurney, M.E. et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775
25. Ling, S-C. et al. (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416-438
26. Martin, N. et al. (2002) A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat. Genet. 32, 443-447
27. Ludolph, A.C. et al. (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. 11, 38-45
28. Bederson, J.B. et al. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472-476
29. Feeney, D.M. et al. (1982) Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217, 855-857
30. Willing, A.E. et al. (2001) hNT neurons delay onset of motor deficits in a model of amyotrophic lateral sclerosis. Brain Res. Bull. 56, 525-530
31. Morita, E. et al. (2008) A novel cell transplantation protocol and its application to an ALS mouse model. Exp. Neurol. 213, 431-438
32. Basso, D.M. et al. (1995) A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12, 1-21
33. Wang, L. et al. (2009) The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol. Dis. 35, 234-240
34. Lasiene, J. and Yamanaka, K. (2011) Glial cells in amyotrophic lateral sclerosis. Neurol. Res. Int. 2011, 718987
35. Philips, T. and Robberecht, W. (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10, 253-263
36. Zhang, Y. et al. (2013) Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 55, 26-35
37. Hall, E.D. et al. (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256
38. Schiffer, D. et al. (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139, 27-33
39. Nagy, D. et al. (1994) Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res. 38, 336-347
40. Kushner, P. et al. (1991) Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J. Neuropath. Exp. Neurol. 50, 263-277
41. Engelhardt, J.I. and Appel, S.H. (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 47, 1210-1216
42. Glass, C.K. et al. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934
43. McGeer, P.L. and McGeer, E.G. (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470
44. Howland, D.S. et al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99, 1604-1609
45. Sekizawa, T. et al. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and noninflammatory central nervous system diseases. J. Neurol. Sci. 154, 194-199
46. Meissner, F. et al. (2010) Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 107, 13046-13050
47. Kiaei, M. et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 26, 2467-2473
48. Trott, A. et al. (2008) Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 19, 1104-1112
49. Kiaei, M. et al. (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2, 246-254
50. Maresz, K. et al. (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 95, 437-445
51. Ehrhart, J. et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflamm. 2, 29
52. Shoemaker, J.L. et al. (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101, 87-98
53. Kim, K. et al. (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542, 100-105
54. Weydt, P. et al. (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. 6, 182-184
55. Neymotin, A. et al. (2009) Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 220, 191-197
56. West, M. et al. (2004) The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J. Neurochem. 91, 133-143
57. Schütz, B. et al. (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805-7812
58. Kiaei, M. et al. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191, 331-336
59. Ferrante, R.J. et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064-2074
60. Wu, A.S. et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurochem. 85, 142-150
61. Petri, S. et al. (2007) The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 102, 991-1000
62. Kupershmidt, L. et al. (2011) Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189, 345-358
63. Kupershmidt, L. et al. (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. Faseb J. 23, 3766-3779
64. Karlsson, J. et al. (2004) Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosurg. 101, 128-137
65. Keep, M. et al. (2001) Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894, 327-331
66. Bordet, T. et al. (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322, 709-720
67. Martin, L.J. (2010) Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs 13, 568-580
68. Rovini, A. et al. (2010) Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem. Pharmacol. 80, 884-894
69. Mattson, M.P. (2000) Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1, 120-130
70. Martin, L.J. (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropath. Exp. Neurol. 58, 459-471
71. Kostic, V. et al. (1997) Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277, 559-563
72. Jiang, H.Q. et al. (2014) Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience 277, 132-138
73. Ryu, H. et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93, 1087-1098
74. Lv, L. et al. (2011) Therapeutic application of histone deacetylase inhibitors for stroke. Cent. Nerv. Syst. Agents Med. Chem. 11, 138-149
75. Lv, L. et al. (2012) Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp. Neurol. 233, 783-790
76. Rothstein, J.D. (1995) Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin. Neurosci. 3, 348-359
77. Rothstein, J.D. (1995) Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv. Neurol. 68, 7-20
78. Bruijn, L.I. et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327-338
79. Trotti, D. et al. (1999) SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 2, 427-433
80. Miller, R.G. et al. (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 1, CD001447
81. Waibel, S. et al. (2004) Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol. 251, 1080-1084
82. Gurney, M.E. et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39, 147-157
83. Del Signore, S.J. et al. (2009) Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 10, 85-94
84. Kalmar, B. et al. (2014) The role of heat shock proteins in amyotrophic lateral sclerosis: the therapeutic potential of arimoclomol. Pharmacol. Ther. 141, 40-54
85. Wang, J. et al. (2009) Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc. Natl. Acad. Sci. U. S. A. 106, 1392-1397
86. Kakkar, V. et al. (2014) Barcoding heat shock proteins to human diseases: looking beyond the heat shock response. Dis. Model. Mech. 7, 421-434
87. Amm, I. et al. (2014) Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochim. Biophys. Acta Mol. Cell Res. 1843, 182-196
88. Kieran, D. et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 10, 402-405
89. Kalmar, B. et al. (2008) Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem. 107, 339-350
90. Wills, A.M. et al. (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383, 2065-2072
91. Stommel, E.W. et al. (2009) Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler. 10, 393-404
92. Lenglet, T. et al. (2014) A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 21, 529-536
93. Dupuis, L. et al. (2012) A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PloS One 7, e37885
94. Lang, A.E. (2010) Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat. Med. 16, 1223-1226
95. Pandya, R.S. et al. (2013) Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 70, 4729-4745
96. Liang, H. et al. (2011) PGC-1α protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 44, 947-956
97. Da Cruz, S. et al. (2012) Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 15, 778-786
98. Holzbaur, E.L. et al. (2006) Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol. Dis. 23, 697-707
99. Morrison, B.M. et al. (2009) A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 217, 258-268